Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

ABSTRACT:

Aim

Associations between antinuclear antibodies (ANAs) and disease severity in nonalcoholic fatty liver disease (NAFLD) remain unclear. This study aimed to provide reliable estimates of ANA prevalence in subjects with biopsy-proven NAFLD and to investigate whether its associations with liver disease severity were established.

Methods

Observational studies measuring ANA in NAFLD patients were derived from the PubMed, Embase, and Web of Science databases from inception to March 30, 2022. The effect size was presented as the pooled risk difference, unstandardized mean differences (MDs), and odds ratio (OR) with a 95% confidence interval (CI).

Results

Thirteen articles involving 2331 patients were finally included. Among the subjects with biopsy-proven NAFLD, the overall

SUBMITTER: Luo L 

PROVIDER: S-EPMC9391168 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature